A Phase 4 interventional study of Somatropin in Hypopituitarism, sponsored by Eli Lilly and Company. Completed at 26 sites in 6 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2007-06-22.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Hypopituitarism with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Hypopituitarism · United States.
Among the 13 studies in Hypopituitarism with a site in United States, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 1999, is one of 2 in phase 4, and was the 5th registered.
47 studies on the registry are indexed under Hypopituitarism; 8 are open to participants now.
Browse Hypopituitarism studies →3 of the 13 studies in Hypopituitarism with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 7–21
Elizabeth Austen Lawson · Sites in United States
Ages 18+
Center for Neurological Studies · Sites in United States
Ages 18–76 · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Hypopituitarism studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 2 · Phase 4 2
First in 1999; this study’s year is marked. 1 started in 1999.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 387 is above the median of 38 across 29 interventional studies indexed under Hypopituitarism.
Median enrollment 41 across the 10 interventional studies, 200 across the 3 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Eli Lilly and Company has 2 studies filed under Hypopituitarism — fewer than ten, so there is no comparison to draw.
2 of the studies in Hypopituitarism with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07568509Massachusetts General HospitalIdentifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease | 2027-04 |
| NCT04789148Elizabeth Austen LawsonEffects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Hypopituitarism with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study tested whether a dose regimen of growth hormone based on body weight is equivalent or better than starting with a low dose and gradually increasing the dose according to individual patient needs. Efficacy of the two regimens were assessed from changes in body fat measured by dual-energy x-ray absorptiometry (DXA) scanning, performed at the beginning of the study and at the completion of the study eight months later.
Dose regimen of growth hormone based on weight: Starting dose was 4.0 micrograms/kg/day for four months, then increased to 8 micrograms/kg/day for two months, and then increased to 12 micrograms/kg/day for a further two months (eight months in total).
Dose regimen of growth hormone based on individual patient needs: Starting dose was 200 micrograms/day, then increased by 200 micrograms/day every two months for an additional six months (eight months in total) as needed for optimal treatment results.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Percent change in total fat mass
Time frame: Eight months
Safety
Time frame: Eight months
The record gives a start of Jan 1999 and a completion of Jul 2001. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone